

March 3, 2016



## Tonix Pharmaceuticals to Present at Two Investor Conferences in March 2016

NEW YORK, March 03, 2016 (GLOBE NEWSWIRE) -- [Tonix Pharmaceuticals Holding Corp.](#) (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix, will present a corporate update twice this month, at conferences sponsored by Cowen & Co. and BioCentury.

Event: 36<sup>th</sup> Annual Cowen & Co. Health Care Conference  
Date: Wednesday, March 9, 2016 at 9:20 a.m. EST  
Location: Boston, MA

Event: 23<sup>rd</sup> Annual BioCentury Future Leaders in the Biotech Industry  
Date: Friday, March 11, 2016 at 10:30 a.m. EST  
Location: New York, NY

In these presentations, Dr. Lederman will provide a corporate update and an overview of Tonix's PTSD and fibromyalgia clinical programs, as Tonix prepares for key data readouts in the coming two quarters.

Both presentations will be webcast live and may be accessed in the Events tab of the Investor Relations page of Tonix's website at [www.tonixpharma.com](http://www.tonixpharma.com). The webcasts will be archived for 60 days.

### About Tonix Pharmaceuticals Holding Corp.

Tonix is developing next-generation medicines for common disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. This press release and further information about Tonix can be found at [www.tonixpharma.com](http://www.tonixpharma.com).

### Safe Harbor / Forward-Looking Statements

*Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our possible need for additional financing; uncertainties of patent protection and litigation;*

*uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2014 and Quarterly Report on Form 10-Q for the period ended September 30, 2015, as filed with the Securities and Exchange Commission (the "SEC") on February 27, 2015 and November 6, 2015, respectively, and future periodic reports filed with the SEC on or after the date hereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.*

Contact:

Bradley J. Saenger  
Chief Financial Officer  
(212) 980-9155 x107  
bradley.saenger@tonixpharma.com

Jenene Thomas Communications (investors)  
Jenene Thomas  
(908) 938-1475  
jenene@jenenethomascommunications.com

Dian Griesel Int'l. (media)  
Susan Forman / Laura Radocaj  
(212) 825-3210  
sforman@dgicomm.com  
lradocaj@dgicomm.com

Source: Tonix Pharmaceuticals Holding Corp.